Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-03-01 @ 4:12 PM
Study NCT ID:
NCT02089334
Status:
TERMINATED
Last Update Posted:
2020-06-30
First Post:
2014-03-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Sponsor:
Rexahn Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-08
Start Date Type:
ACTUAL
Primary Completion Date:
2018-04-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-05-17
Completion Date Type:
ACTUAL
First Submit Date:
2014-03-13
First Submit QC Date:
None
Study First Post Date:
2014-03-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-05-18
Results First Submit QC Date:
None
Results First Post Date:
2020-06-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-15
Last Update Post Date:
2020-06-30
Last Update Post Date Type:
ACTUAL